Shao-Lee Lin, Acelyrin CEO
September 11, 2023 04:05 PM EDTUpdated 04:47 PM
R&D

Ace­lyrin's IL-17 in­hibitor fails to hit pri­ma­ry end­point in key study af­ter splashy IPO

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times